MMMohamed-Eslam F. Mohamed

Mohamed-Eslam F. Mohamed

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Mohamed-Eslam F. Mohamed has a total of 216 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Efficacy, Safety, and Pharmacokinetics of Upadacitinib Among Patients in East Asia With Moderately to Severely Active Ulcerative Colitis: A Post Hoc Subanalysis of Randomized Phase 3 Studies

    by Shu Chen Wei, Hiroshi Nakase, Byong Duk Ye, Kang Chao, Hsin‐Yun Wu, Jason Eccleston, Xuan Yao, Hannah Palac, Mohamed‐Eslam F. Mohamed, Ana Victoria Ponce‐Bobadilla, et al.

    Background and Aim: Upadacitinib, a selective Janus kinase 1 inhibitor, is approved to treat moderately to severely active ulcerative colitis (UC). This post hoc subanalysis evaluated the efficacy, safety, and pharmacokinetics of upadacitinib in patients in East Asia. Methods: U‐ACHIEVE (UC1; NCT02819635) and U‐ACCOMPLISH (UC2; NCT03653026) were Phase 3, multicenter, randomized, double‐blind, induction studies evaluating upadacitinib 45 mg or placebo daily in adults with moderately to severely active UC. Clinical responders to 8 weeks of upadacitinib induction were eligible to receive upadacitinib 15 mg, upadacitinib 30 mg, or placebo daily in the 52‐week U‐ACHIEVE maintenance study (UC3; NCT02819635). Efficacy outcomes, safety, and pharmacokinetics were evaluated among East Asian patients. Results: A higher proportion of East Asian patients achieved clinical remission with upadacitinib than placebo at induction Week 8 (UC1: n = 127, 31.4% vs. 7.3%; UC2: n = 114, 31.2% vs. 2.7%) and maintenance Week 52 (UC3: n = 184, upadacitinib 15 mg, 52.4%; upadacitinib 30 mg, 53.8%; placebo, 10.7%). Rates of endoscopic outcomes were higher with upadacitinib than with placebo across studies. No new safety signals were identified. Herpes zoster occurrences were low (UC1 and UC2: upadacitinib 45 mg, two events [in one patient]; placebo, zero events; UC3: upadacitinib 15 mg, five events; upadacitinib 30 mg, eight events; placebo, zero events). Pharmacokinetics and trends in the relationship between upadacitinib exposure and efficacy were consistent in the East Asian and global populations. Conclusion: Upadacitinib was generally well tolerated and effective for treating moderately to severely active UC in patients in East Asia, with a favorable benefit–risk profile consistent with the global population. Trial Registration: ClinicalTrials.gov identifier: NCT02819635, NCT03653026


  • Epcoritamab Step‐Up Dosing Regimen Selection and Optimization Using Repeated Time‐to‐Event Modeling for Cytokine Release Syndrome Risk Mitigation

    by Tommy Li, Andrew Tredennick, Daniel Polhamus, Matthew Putnins, Sihang Liu, Kinjal Sanghavi, Craig J. Thalhauser, Apurvasena Parikh, Behnam Noorani, Mohamed‐Eslam F. Mohamed, et al.

    Epcoritamab is a CD3 × CD20 T‐cell–engaging bispecific antibody approved for the treatment of various types of relapsed/refractory (R/R) large B‐cell lymphoma (LBCL) and R/R follicular lymphoma (FL), after at least two lines of systemic therapy. Here, we develop and calibrate repeated time‐to‐event models to assess the impact of optimized step‐up dosing (SUD) regimens and the effect of intravenous fluids and/or corticosteroids on cytokine release syndrome (CRS) risk. The analysis used pooled data from 600 patients with aggressive non‐Hodgkin lymphoma (aNHL) and indolent NHL (iNHL) who received subcutaneous epcoritamab in 28‐day cycles in the EPCORE® NHL‐1 and EPCORE® NHL‐3 studies (NCT03625037, NCT04542824). In the calibrated model, prior CAR T cell therapy (125/600 patients [20.8%]) was associated with a 69.7% reduction (95% confidence interval [CI], 38.2–85.2) in the maximum stimulatory effect of epcoritamab on the hazard of Grade ≥2 CRS. Intravenous fluids or dexamethasone during Cycle (C)1 were associated with a 2.89‐fold (95% CI, 1.57–5.30) increase in the half‐maximal effective plasma concentration of epcoritamab on stimulation (S50). Furthermore, prophylaxis with intravenous fluids and dexamethasone during C1 was associated with a 3.79‐fold (95% CI, 1.65–8.73) increase in S50. Simulations show that the use of dexamethasone further reduces Grade ≥2 CRS risk compared with prednisone in patients with aNHL/iNHL. Moreover, a 3‐SUD design further reduces CRS risk in patients with iNHL. Overall, our models showed that the approved 2‐SUD regimen for R/R LBCL and 3‐SUD regimen for R/R FL—together with intravenous fluids and dexamethasone prophylaxis—are adequate to reduce Grade ≥2 CRS risk.

  • Model‐Informed Dosing Strategies for Epcoritamab Monotherapy in Relapsed or Refractory Large B‐Cell Lymphoma

    by Xiaozhi Liao, Tommy Li, Steven Xu, Mohamed‐Eslam F. Mohamed, Mahipal Sinnollareddy, Manish Gupta, Monica Wielgos‐Bonvallet, Andrew J. Steele, Mariana Sacchi, Yanguang Cao

    Dose selection is a central challenge in drug development, and direct evaluation of alternative regimens is often ethically difficult. We developed a joint model integrating pharmacokinetics, pharmacodynamics, and Deauville score to evaluate alternative dosing strategies for a CD3 × CD20 bispecific antibody, epcoritamab, as monotherapy in relapsed or refractory (R/R) large B‐cell lymphoma (LBCL) after ≥2 lines of systemic therapy. The model was developed using clinical data from 165 patients and simultaneously described plasma epcoritamab concentrations, tumor burden dynamics, and longitudinal Deauville scores. Simulations were conducted in 1,000 virtual patients to evaluate three post‐complete response (CR) dosing strategies: continuous, fixed‐duration, and stop‐at‐CR. Responder subgroups were defined based on CR durability, and predictors of patients likely to require continuous treatment were explored. Simulations indicated that continued epcoritamab treatment after CR was associated with higher simulated CR rates over the long term, with simulated 2‐year CR rates of 46.4% (continuous), 37.2% (fixed‐duration), and 27.0% (stop‐at‐CR). Exploratory analyses suggested that indicators of residual disease, such as limited early tumor reduction and elevated circulating tumor DNA levels, help identify patients most likely to benefit from continuous treatment. This modeling framework provides a quantitative approach for evaluating alternative dosing strategies for epcoritamab monotherapy in R/R LBCL and supports the potential value of continuous therapy in maintaining long‐term CR, as suggested by model‐based simulations. However, this study focuses solely on efficacy outcomes; therefore, further validation and incorporation of safety outcomes are needed to fully support clinical decision‐making and regimen optimization.

  • Open Access

    Effects of Cedirogant on the Pharmacokinetics of Sensitive Cytochrome P450 Probe Substrates

    by Ronilda D'CUnha, Yuli Qian, Shuai Hao, Jason Eccleston, Gweneth F. Levy, Shashikanth Gannu, David G. Rizzo, Wei Liu, Mohamed‐Eslam F. Mohamed

    This study aimed to characterize the effects of cedirogant, an inverse agonist of retinoic acid–related orphan receptor gamma thymus (RORγt), on activities of cytochrome P450 (CYP) enzymes in healthy adults. Twenty study participants received a single oral dose of the modified Cooperstown 5+1 cocktail CYP probe drugs alone without cedirogant (Period 1, midazolam on Day 1 and other CYP substrates on Day 2), and again following once‐daily dosing of 375 mg cedirogant (Period 2, cedirogant on Days 1‐18, midazolam on Day 13, and other CYP substrates on Day 14). Blood samples and 12‐hour urine samples were collected to measure the exposures of the CYP probe drugs and selected metabolites. The point estimates (90% confidence intervals) of the area under the plasma concentration–time curve from time 0 to infinity (AUC inf ) ratio with and without cedirogant co‐administration were 0.370 (0.325‐0.420) for midazolam (CYP3A), 1.161 (1.031‐1.307) for caffeine (CYP1A2), and 0.788 (0.761‐0.816) for S‐Warfarin (CYP2C9). The estimated ratios of plasma metabolite/parent AUC ratio for omeprazole (CYP2C19) and parent/metabolite molar urine recovery ratio for dextromethorphan (CYP2D6) with versus without cedirogant co‐administration were 2.115 (1.813‐2.467) and 0.951 (0.802‐1.128), respectively. Based on these findings, once‐daily administration of 375‐mg cedirogant showed moderate induction of CYP3A and CYP2C19, a weak effect on CYP2C9, and no clinically relevant effects on CYP1A2 or CYP2D6.

  • Open Access

    Generating Control Groups for Organ Impairment Studies: A Case‐Study Comparing Statistical and Population Pharmacokinetic‐Based Matching Approaches

    by Jessica Barry, Sumit Bhatnagar, Wei Liu, Mohamed‐Eslam F. Mohamed

    A common challenge in conducting phase 1 studies that assess the impact of organ impairment on the pharmacokinetics of a drug is the recruitment of a demographically matched control group. The work presented here evaluated alternative approaches for generating control groups in these studies. Available phase 1 data from the upadacitinib and elagolix clinical programs were leveraged as case studies. A statistical matching approach and a population pharmacokinetic model‐based approach were evaluated retrospectively for these programs' hepatic and renal impairment clinical studies. Geometric mean ratios of logarithmically transformed C max and AUC inf were used to compare exposure in organ impairment groups to respective matched or virtual control groups. In the statistical matching approach, the genetic matching algorithm using Mahalanobis distance showed that external control groups were adequately demographically balanced across all impairment groups of the study except for age. A 3:1 k‐match approach minimized the prediction error between matched and reference in‐study results for both case studies, resulting in differences in geometric mean ratios ranging from −19% to 3% and −27% to 40% for upadacitinib and elagolix, respectively, compared to in‐study controls. Similarly, the population pharmacokinetic approach used models developed from phase 1 data in healthy participants and found that the results were generally comparable to the in‐study results, with differences in geometric mean ratios ranging from −30% to 17% and −24% to 41% for upadacitinib and elagolix, respectively. These analyses demonstrate that both approaches may be viable alternatives to assess the impact of organ impairment on pharmacokinetics.


  • Open Access

    Model‐Informed Paradigm in Drug Development—An End‐To‐End Case Study From Upadacitinib Development

    by Sumit Bhatnagar, Sven Stodtmann, Yuli Qian, Patrick Marroum, Wei Liu, Mohamed‐Eslam F. Mohamed

    Model‐informed drug development (MIDD) entails applying quantitative approaches to assist with decision‐making during drug development and has been used for dose optimization, to inform clinical trial design, and to support clinical trial waivers. With increasing cost and competitiveness in drug development, the use of tools that improve efficiency, like MIDD, is increasingly crucial. A unique case for the successful application of MIDD approaches from early Phase 1 through postapproval for the upadacitinib development program is described herein. Upadacitinib is an orally administered selective Janus kinase inhibitor, which is approved for rheumatoid arthritis, psoriatic arthritis, atopic dermatitis, axial spondylarthritis, nonradiographic axial spondyloarthritis, ulcerative colitis, and Crohn's disease for adults, in addition to recent approvals for polyarticular juvenile idiopathic arthritis and pediatric patients with psoriatic arthritis. Applications and impact of modeling and simulation approaches for informing key development decisions are presented to highlight the success of using MIDD for the clinical development of upadacitinib. The lessons learned can provide a framework for the clinical development of other drugs.


  • Open Access

    Pharmacokinetics, Efficacy, and Safety of Upadacitinib in Pediatric Patients With Polyarticular‐Course Juvenile Idiopathic Arthritis: An Interim Analysis of an Open‐Label, Phase 1 Trial

    by Hermine I. Brunner, Anna Shmagel, Gerd Horneff, Ivan Foeldvari, Jordi Antón, Athimalaipet V. Ramanan, Yuli Qian, Kristina Unnebrink, Shuai Hao, Heidi S. Camp, et al.

    Objective: This work aimed to evaluate the pharmacokinetics, efficacy, and safety of upadacitinib, an oral selective JAK inhibitor, in pediatric patients with polyarticular‐course juvenile idiopathic arthritis (pcJIA).Methods: In an open‐label, phase 1 study (SELECT‐YOUTH), enrolled patients, aged 2 to <18 years with pcJIA, received body weight–based upadacitinib doses using a twice‐daily oral solution or once‐daily extended‐release tablet based on their body weight and ability to swallow tablets. The study included a 7‐day pharmacokinetic assessment, followed by a long‐term efficacy and safety evaluation for up to 156 weeks, including an additional long‐term safety cohort. This interim analysis included available pharmacokinetic and safety data and efficacy data collected through week 48.Results: A total of 57 patients received upadacitinib. The median time to maximum upadacitinib concentration was approximately three hours and one hour for the tablet and oral solution regimens, respectively; the harmonic mean functional half‐life was approximately five hours and two hours, respectively. Juvenile idiopathic arthritis American College of Rheumatology 30, 50, 70, 90, and 100 responses at week 12 were 91.8%, 89.8%, 69.4%, 49.0%, and 32.7%, respectively. Efficacy was generally maintained through week 48, and improvement in additional efficacy end points was also observed. At a median exposure duration of 412 days, 52 of 57 patients reported adverse events; of these, 6 experienced serious adverse events. Adverse events were predominately mild to moderate in severity and consistent with the known safety profile of upadacitinib.Conclusion: This interim analysis demonstrates that the bodyweight‐based dosing regimen of upadacitinib was well tolerated and efficacious in pediatric patients with pcJIA.


  • Open Access

    Endogenous plasma riboflavin is not a viable BCRP biomarker in human

    by John P. Savaryn, Ryota Kikuchi, Yuli Qian, Qin C. Ji, Gary J. Jenkins, Daniel A. J. Bow, Mohamed‐Eslam F. Mohamed

    Recent reports suggest that plasma riboflavin may serve as a biomarker for BCRP inhibition in humans. However, the clinical data supporting this claim have been limited, with only two studies showing modest increases in riboflavin levels after administration of a BCRP inhibitor. We have recently demonstrated that co‐administration of 375 mg once daily (q.d.) cedirogant, an in vitro BCRP inhibitor, significantly increased rosuvastatin (an OATP1B1/1B3 and BCRP substrate) exposures but did not change the levels of the OATP1B endogenous biomarker coproporphyrin‐I, demonstrating that cedirogant is a clinical BCRP inhibitor. Samples from this same cedirogant clinical drug–drug interaction study were utilized to test the hypothesis that endogenous plasma riboflavin is a biomarker of BCRP inhibition. Plasma riboflavin levels in the absence of cedirogant ranged from 1 to 10 ng/mL across the 11 participants analyzed with minimal (<20%) intrasubject variability over a 24‐hour interval. Contrary to expectations, 375 mg q.d. oral administration of cedirogant did not increase riboflavin levels. These data strongly suggest that endogenous plasma riboflavin is not a viable biomarker for BCRP inhibition in humans.


  • Open Access

    Extrapolation of Upadacitinib Efficacy in Juvenile Idiopathic Arthritis Leveraging Pharmacokinetics, Exposure–Response Models, and Real‐World Patient Data

    by Yuli Qian, Louisa Schlachter, Doerthe Eckert, Sven Stodtmann, Anna Shmagel, Yi Peng, Wei Liu, Mohamed‐Eslam F. Mohamed

    Juvenile idiopathic arthritis (JIA) is the most prevalent pediatric rheumatic disease. While disease‐modifying antirheumatic drugs (DMARDs), especially biologics, have greatly transformed the management of JIA, there remain some unmet medical needs that require new treatment options. The objective of this work was to describe and apply a modeling and simulation approach to extrapolate upadacitinib efficacy from the adult diseases, rheumatoid arthritis (RA) and psoriatic arthritis (PsA), to their respective pediatric diseases, polyarticular course JIA (pcJIA), and juvenile PsA (JPsA). A population pharmacokinetic model characterized upadacitinib pharmacokinetics in pediatric patients using data from two phase I studies in pediatric patients with pcJIA (N = 51) or atopic dermatitis (N = 33). Efficacy simulations were conducted using previously developed exposure–response models in adults with RA and PsA. Real‐world pcJIA and JPsA patient databases were leveraged to construct representative patient profiles for the targeted population. Following administration of the proposed weight‐based dosing regimen, the model‐predicted median upadacitinib plasma exposures in pediatric patients were within 20% of those in adult RA and PsA patients receiving the approved adult regimen. Simulations demonstrate that upadacitinib efficacy in pcJIA and JPsA is predicted to be non‐inferior to that in adults with RA or PsA, respectively. The results of this work enabled recent approvals of upadacitinib for the treatment of polyarticular JIA and JPsA in the United States. Upadacitinib safety in pediatrics is being further evaluated in ongoing clinical trials.


  • Pharmacokinetics, Safety, Tolerability, and Exploratory Efficacy of Upadacitinib in Children with Severe Atopic Dermatitis

    by Yuli Qian, Eliza M. Raymundo, Shuai Hao, Kristina Unnebrink, Gweneth F. Levy, Henrique D. Teixeira, Alvina D. Chu, Zachary A. Zinn, Amy S. Paller, Wei Liu, et al.